文献速递肾移植肾小球疾病

肾小球肾炎移植前免疫抑制治疗与肾移植受者恶性肿瘤风险

Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

单中心回顾性研究纳入肾小球肾炎为原发病并接受移植前免疫抑制治疗(PTI)的肾移植受者184例,与非糖尿病、未接受PTI的对照579例比较。中位随访5.7年,PTI组恶性肿瘤风险显著升高(13.0% vs 9.7%,校正HR 1.82,95%CI 1.10-3.00),非黑色素瘤皮肤癌和移植后淋巴增殖性疾病风险无显著差异。

要点

  • 肾小球肾炎患者移植前免疫抑制治疗与移植后恶性肿瘤风险升高相关(校正HR 1.82)。
  • 移植前使用环磷酰胺(HR 2.59)或利妥昔单抗(HR 3.82)者恶性肿瘤风险显著增加。
  • 非黑色素瘤皮肤癌和移植后淋巴增殖性疾病风险与对照相比无显著差异。

核心结论

  • 肾小球肾炎移植前免疫抑制治疗,尤其是使用环磷酰胺或利妥昔单抗,与移植后实体或血液系统恶性肿瘤风险增加相关。

研究设计与样本

  • 单中心回顾性研究,纳入2005年1月至2020年5月肾移植受者,PTI组184例,对照组579例(非糖尿病、未接受PTI)。

主要发现

  • 中位随访5.7年,PTI组恶性肿瘤发生率13.0% vs 对照组9.7%,校正HR 1.82(95%CI 1.10-3.00)。
  • 非黑色素瘤皮肤癌发生率PTI组10.3% vs 对照组11.4%,校正HR 1.09(95%CI 0.64-1.83)。
  • 移植后淋巴增殖性疾病发生率PTI组3.3% vs 对照组3.1%,校正HR 1.02(95%CI 0.40-2.61)。
  • 移植前使用环磷酰胺者恶性肿瘤风险HR 2.59(95%CI 1.48-4.55),使用利妥昔单抗者HR 3.82(95%CI 1.69-8.65),两者联用风险尤其升高。
  • 使用钙调神经磷酸酶抑制剂或霉酚酸酯者未见恶性肿瘤风险显著增加。

临床怎么用

  • 作者认为这些数据提示治疗肾小球肾炎的潜在风险,并强调对该患者群体进行移植后恶性肿瘤监测的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney transplant patients with glomerulonephritis (GN) as their native disease may receive significant amounts of pre-transplant immunosuppression (PTI), which could increase the risk for development of malignancy post-transplant. METHODS: We conducted a single-center, retrospective study of kidney transplant recipients from January 2005 until May 2020. Patients with GN as their native kidney disease who received PTI for treatment of GN (n = 184) were compared with a control cohort (n = 579) of non-diabetic, non-PTI-receiving kidney transplant patients. We calculated hazard ratios (HR) with 95% confidence intervals (95% CI) for outcomes of first occurrence of solid or hematologic malignancy, non-melanoma skin cancer (NMSC) and post-transplant lymphoproliferative disorder (PTLD). RESULTS: Over a median follow-up of 5.7 years, PTI for GN was associated with significantly increased risk for malignancy compared with controls [13.0% vs 9.7%, respectively; adjusted HR 1.82 (95% CI 1.10-3.00)], but not for NMSC [10.3% vs 11.4%, respectively; adjusted HR 1.09 (95% CI 0.64-1.83)] or PTLD [3.3% vs 3.1%, respectively; adjusted HR 1.02 (95% CI 0.40-2.61)]. The risk for malignancy was significantly increased in those who received cyclophosphamide [HR 2.59 (95% CI 1.48-4.55)] or rituximab [HR 3.82 (95% CI 1.69-8.65)] pre-transplant, and particularly in those who received both cyclophosphamide and rituximab, but not for calcineurin inhibitors or mycophenolate. CONCLUSION: The use of PTI for treatment of GN, especially cyclophosphamide or even with rituximab, is associated with increased risk for development of solid or hematologic malignancy post-transplant. These data highlight potential risks with treatment of GN and underscore the importance of post-transplant malignancy surveillance in this patient population.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Massicotte-Azarniouch D, Detwiler RK, Hu Y, et al. Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis. Nephrol Dial Transplant. 2023. PMID: 36549661. doi:10.1093/ndt/gfac337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。